Marché mondial des médicaments contre l’ostéomyélite – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché mondial des médicaments contre l'ostéomyélite

L'incidence de l'ostéomyélite a augmenté ces dernières années, créant de bonnes conditions pour l'expansion de l'industrie. Selon le Centre national d'information sur la biotechnologie, le taux annuel mondial d'incidence de l'ostéomyélite était de 13 pour 100 000 en 2016. En raison de l'incidence croissante de l'ostéomyélite, il y aura une forte demande de thérapies, propulsant le marché mondial de l'ostéomyélite vers l'avant. Cela a encore accru la demande de médicaments contre l'ostéomyélite sur le marché.

• Français Data Bridge Market Research analyse que le marché des médicaments contre l'ostéomyélite était évalué à 1,34 milliard USD en 2021 et devrait atteindre 2,29 milliards USD d'ici 2029, enregistrant un TCAC de 6,90 % au cours de la période de prévision de 2022 à 2029. Le rapport de marché organisé par l'équipe de recherche sur le marché Data Bridge comprend une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Définition du marché mondial des médicaments contre l'ostéomyélite

L'ostéomyélite, une infection osseuse, est causée par des bactéries ou des champignons. Le gonflement provoqué par cette infection osseuse douloureuse peut endommager l'os et entraîner une perte osseuse. Les antibiotiques sont souvent efficaces lorsqu'ils sont utilisés rapidement. Une intervention chirurgicale peut être nécessaire pour drainer les abcès ou retirer l'os endommagé chez certaines personnes. L'ostéomyélite est plus fréquente chez les jeunes enfants, les personnes âgées et les personnes atteintes de diabète.

Portée du rapport et segmentation du marché

Dynamique du marché des médicaments contre l'ostéomyélite

Conducteurs

• Prévalence croissante des maladies chroniques

Le marché des médicaments contre l'ostéomyélite est stimulé par une augmentation de la prévalence des maladies chroniques. L'ostéomyélite est plus fréquente chez les personnes souffrant de problèmes de santé chroniques, notamment le diabète ou l'insuffisance rénale. Si une personne est diabétique et a des ulcères du pied, elle peut être atteinte d'ostéomyélite.     

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important influençant le taux de croissance du marché des médicaments contre l’ostéomyélite est l’augmentation des dépenses de santé qui contribuent à améliorer son infrastructure.

En outre, les initiatives croissantes des organismes publics et privés visant à sensibiliser le public élargiront le marché des médicaments contre l'ostéomyélite. De plus, le revenu disponible élevé et le nombre croissant de personnes âgées entraîneront l'expansion du marché des médicaments contre l'ostéomyélite. Parallèlement à cela, les politiques gouvernementales favorables et l'augmentation de l'incidence du tabagisme augmenteront le taux de croissance du marché.

Opportunités

• Augmentation du nombre d'activités de recherche et développement       

De plus, la croissance du marché est alimentée par une augmentation du nombre d'activités de recherche et développement. Cela offrira des opportunités bénéfiques pour la croissance du marché des médicaments contre l'ostéomyélite. Parallèlement à cela, l'augmentation des approbations et des lancements de médicaments propulsera davantage le taux de croissance du marché.

De plus, l’augmentation des investissements dans le développement de technologies avancées et l’augmentation du nombre de marchés émergents offriront davantage d’opportunités bénéfiques pour la croissance du marché des médicaments contre l’ostéomyélite au cours de la période de prévision.

Contraintes/Défis du marché mondial des médicaments contre l'ostéomyélite

• Medical reimbursement for osteomyelitis

Medical reimbursement for osteomyelitis is a major stumbling block. Medical reimbursement is one of the most important factors determining the acceptance and demand of particular diagnostic and therapeutic items among health care professionals and patients at the national level. Many private insurance companies do not cover or reimburse osteomyelitis surgeries.

On the other hand, the high cost associated with the treatment and osteomyelitis drugs will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the osteomyelitis drugs market. Additionally, impact of COVID-19 on supply chain and the dearth of awareness will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This osteomyelitis drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the osteomyelitis drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The overall incidence of osteomyelitis in the United States is unknown, however reports suggest that it affects as many as 1 in 675 hospital admissions in the United States each year, or approximately 50,000 cases. According to other studies, there are 21.8 instances of osteomyelitis per 100,000 person-years. For unexplained reasons, the frequency was higher in men, although it rises with age, owing to an increase in the prevalence of comorbid conditions such as diabetes and peripheral vascular disease.

Osteomyelitis drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Osteomyelitis Drugs Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The osteomyelitis drugs market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the osteomyelitis drugs market's revenue trajectory.

Recent Development

• In January 2021, Locate Bio, has been awarded Food and Drug Administration (FDA) breakthrough device designation for CognitOss. Surgical debridement, long-term, high-dose antibiotic therapy, and – for larger lesions – bone grafting, which typically necessitates a second surgical surgery to remove the non-resorbable bone graft, are currently the primary treatments for chronic osteomyelitis.

Global Osteomyelitis Drugs Market Scope

The osteomyelitis drugs market is segmented on the basis of disease type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Acute Osteomyelitis
• Chronic Osteomyelitis
• Vertebral Osteomyelitis

On the basis of disease type, the osteomyelitis drugs market is segmented into acute osteomyelitis, chronic osteomyelitis, and vertebral osteomyelitis.

Treatment

• Medication
• Surgery
• Others

On the basis of treatment, the osteomyelitis drugs market is segmented into medication, surgery and others. Medication segment is further segmented into antibiotics, antifungals, nonsteroidal anti-inflammatory drugs (NSAIDs) and others.

Diagnosis

• Blood Test
• Imaging Test
• Bone Biopsy
• Others

On the basis of diagnosis, the osteomyelitis drugs market is segmented into blood test, imaging test, bone biopsy, and others. Imaging test further segmented into X-rays, MRI, CT scan and others.

Route of Administration

• Oral
• Parenteral
• Topical
• Others

Route of administration segment of osteomyelitis drugs market is segmented into oral, parenteral, topical and others.

End-Users

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

On the basis of end-users, the osteomyelitis drugs market is segmented into hospitals, specialty clinics, home healthcare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the osteomyelitis drugs market has also been segmented into hospital pharmacy, retail pharmacy, and others

Osteomyelitis Drugs Market Regional Analysis/Insights

The osteomyelitis drugs market is analysed and market size insights and trends are provided by country, type, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the osteomyelitis drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the osteomyelitis drugs market because of the advancement in technology and growing prevalence of infectious diseases in this region. Additionally, the presence of major key players will enhance the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to rising number of joint replacement surgeries and swiftly improving healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Osteomyelitis Drugs Market Share Analysis

The Osteomyelitis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to osteomyelitis drugs market.

Some of the major players operating in the osteomyelitis drugs market are

• Johnson & Johnson Private Limited (US)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd.(Jerusalem)
• Sanofi (France)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (UK)
• AbbVie Inc. (US)
• Novartis AG (Switzerland)
• Eli Lilly and Company (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Merck & Co., Inc. (US)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• AstraZeneca (UK)
• Abbott (US)
• Sun Pharmaceutical Industries Ltd. (Bombay)
• Aurobindo Pharma (Hyderabad)
• Lupin (Bombay)
• Nabriva Therapeutics plc. (Irlande)
• Vyome Therapeutics Inc. (Delhi)
• Debiopharm (Suisse)

SKU-55727